iCAD, Inc. is a global medical technology leader dedicated to creating a world where cancer can't hide. Specializing in innovative, AI-powered breast health solutions, iCAD empowers healthcare providers to detect cancer earlier and improve patient outcomes. Their flagship product, the ProFound Breast Health Suite, offers advanced mammography analysis for breast cancer detection, density assessment, and risk evaluation. With FDA clearance, CE marking, and Health Canada licensing, ProFound is utilized by thousands of providers across more than 50 countries, contributing to the analysis of over 40 million mammograms worldwide in the past five years. Key Features and Functionality: - ProFound AI®: An AI-driven solution that rapidly and accurately analyzes digital breast tomosynthesis (DBT) images, detecting malignant soft tissue densities and calcifications with high sensitivity. - Breast Density Assessment: Provides objective evaluations of breast density, aiding in personalized treatment planning and addressing the increased risk associated with dense breast tissue. - Risk Evaluation: Utilizes image-based risk modeling to identify high-risk patients more effectively than traditional methods, enabling timely interventions. - Seamless Integration: Designed to integrate smoothly with existing radiology systems, enhancing workflow efficiency and reducing reading times for radiologists. Primary Value and User Benefits: iCAD's solutions address critical challenges in breast cancer detection by enhancing diagnostic accuracy and operational efficiency. By leveraging advanced AI algorithms, healthcare providers can detect cancers earlier, including invasive lobular carcinomas, leading to improved patient care and outcomes. The ProFound Breast Health Suite also reduces unnecessary recalls and biopsies, minimizes reading times, and alleviates radiologist workload, ultimately contributing to a more effective and patient-centric approach to breast health management.